Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Launches COVID-19 Test For Cobas System; BioMérieux Plans Three COVID-19 Tests

Executive Summary

Roche announced that the US FDA has granted an Emergency Use Authorization for the cobas SARS-CoV-2 test for patients suspected to have COVID-19. bioMérieux is planning three COVID-19 tests.

You may also be interested in...



COVID-19 Testing Boosts Roche Diagnostics Sales In H1

Roche's diagnostics division grew 3% in the first half of 2020 with exploding demand for COVID-19 tests offsetting declines in routine testing.

‘Diagnostics Has Been Underestimated’: COVID-19 Testing Drives Roche Diagnostics Q1 Sales

Roche's diagnostics sales increased 5% to $2.93bn in the first quarter of 2020. Molecular diagnostics was the main growth contributor, driven by demand for COVID-19 tests and automated testing systems.

UK Govt Buys 3.5M 15-Minute COVID-19 Antibody Home Tests From Mystery Manufacturer

The UK government has ordered 3.5 million home test kits to identify people who have antibodies to the SARS-CoV-2 virus. However, it has not said who will supply the test kits.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT126384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel